| Literature DB >> 28623298 |
Luana Presta1, Emanuele Bosi1, Leila Mansouri1, Lenie Dijkshoorn2, Renato Fani1, Marco Fondi3.
Abstract
Acinetobacter baumannii is a clinical threat to human health, causing major infection outbreaks worldwide. As new drugs against Gram-negative bacteria do not seem to be forthcoming, and due to the microbial capability of acquiring multi-resistance, there is an urgent need for novel therapeutic targets. Here we have derived a list of new potential targets by means of metabolic reconstruction and modelling of A. baumannii ATCC 19606. By integrating constraint-based modelling with gene expression data, we simulated microbial growth in normal and stressful conditions (i.e. following antibiotic exposure). This allowed us to describe the metabolic reprogramming that occurs in this bacterium when treated with colistin (the currently adopted last-line treatment) and identify a set of genes that are primary targets for developing new drugs against A. baumannii, including colistin-resistant strains. It can be anticipated that the metabolic model presented herein will represent a solid and reliable resource for the future treatment of A. baumannii infections.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28623298 PMCID: PMC5473915 DOI: 10.1038/s41598-017-03416-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Comparison between in silico and wet-lab experimental outcomes.
Number of genes in the model per COG categories.
| COG Functional Category | Description | N. of genes |
|---|---|---|
| J | Translation, ribosomal structure and biogenesis | 28 |
| A | RNA processing and modification | 0 |
| K | Transcription | 11 |
| L | Replication, recombination and repair | 21 |
| B | Chromatin structure and dynamics | 0 |
| D | Cell cycle control, cell division, chromosome partitioning | 1 |
| Y | Nuclear structure | 0 |
| V | Defense mechanisms | 4 |
| T | Signal transduction mechanisms | 5 |
| M | Cell wall/membrane/envelope biogenesis | 60 |
| N | Cell motility | 0 |
| Z | Cytoskeleton | 0 |
| W | Extracellular structures | 0 |
| U | Intracellular trafficking, secretion, and vesicular transport | 0 |
| O | Posttranslational modification, protein turnover, chaperones | 20 |
| C | Energy production and conversion | 120 |
| G | Carbohydrate transport and metabolism | 61 |
| E | Amino acid transport and metabolism | 182 |
| F | Nucleotide transport and metabolism | 57 |
| H | Coenzyme transport and metabolism | 82 |
| I | Lipid transport and metabolism | 97 |
| P | Inorganic ion transport and metabolism | 71 |
| Q | Secondary metabolites biosynthesis, transport and catabolism | 16 |
| R | General function prediction only | 32 |
| S | Function unknown | 12 |
| X | No Functional Class Found | 15 |
Figure 2GRratio value for each gene deletion in rich (A) and minimal (B) media. Blue and red lines represent MOMA and FBA predictions, respectively. Please note that, in order to make the analysis more comprehensive, also gap-filling genes (i.e. those virtually coding for gap-filling reactions) were included, leading to a total of 1043 simulated knock-outs.
Figure 3(A) A venn diagram proportionally showing EGs predicted only in Simmons medium (pink), EGs predicted only in rich medium (green), and EGs predicted by both (blue). (B) A venn diagram proportionally showing EGs predicted in silico only by iLP844 (pink), EGs obtained only by wet-lab experiment in ATCC 17978 (green), and EGs predicted by both methods (blue). (C) A venn diagram proportionally showing essential reactions predicted in iLP844 (pink), essential reactions predicted only in A. baumannii AYE model (AbyMBEL891) (green), and essential reactions predicted by both (blue). (D) A venn diagram proportionally showing EGs predicted only in iLP844 (pink), EGs predicted only by wet-lab experiment in A. baumannii ATCC 19606 cell (green), and EGs predicted by both (blue).
Figure 4Abundance plot of reactions affected by colistin treatment at 15 (blue) and 60 (pink) minutes arranged according to three categories: ‘steady’, ‘increasing’, ‘decreasing’. Pathways which they belong to are reported.
Complete set of condition specific EGs found. “Yes” and “no” refet to gene essentiality in the corresponding condition.
| Locus Tag | Function | 15′ without colistin | 15′ with colistin | 60′ without colistin | 60′ with colistin | LPS− without colistin | LPS− with colistin |
|---|---|---|---|---|---|---|---|
| HMPREF0010_00435 | phosphopyruvate hydratase | yes | no | yes | no | no | no |
| HMPREF0010_00813 | fructose-bisphosphate aldolase class II Calvin cycle subtype | yes | no | yes | no | no | no |
| HMPREF0010_00815 | phosphoglycerate kinase | yes | no | yes | no | no | no |
| HMPREF0010_00975 | amino acid ABC transporter periplasmic protein | yes | no | yes | no | no | no |
| HMPREF0010_01733 | PAP2 superfamily protein | yes | no | yes | no | no | no |
| HMPREF0010_01995 | 23-bisphosphoglycerate-independent phosphoglycerate mutase | yes | no | yes | no | no | no |
| HMPREF0010_02140 | fructose-16-bisphosphatase | yes | no | yes | no | no | no |
| HMPREF0010_03273 | glucose-6-phosphate isomerase | yes | no | yes | no | no | no |
| HMPREF0010_00382 | phosphotransferase system fructose-specific EI/HPr/EIIA component | yes | no | yes | no | no | no |
| HMPREF0010_03275 | UTP-glucose-1-phosphate uridylyltransferase | yes | no | yes | no | no | no |
| HMPREF0010_01305 | alphaalpha-trehalose-phosphate synthase (UDP-forming) | yes | no | yes | no | no | no |
| HMPREF0010_01353 | glutamine-dependent NAD+ synthetase | yes | no | no | no | no | no |
| HMPREF0010_00342 | ornithine carbamoyltransferase | no | yes | no | no | no | yes |
| HMPREF0010_00949 | malonate decarboxylase epsilon subunit | no | yes | no | yes | no | no |
| HMPREF0010_01149 | acetyl-CoA carboxylase biotin carboxylase | no | yes | no | no | no | no |
| HMPREF0010_01969 | argininosuccinate lyase | no | yes | no | yes | no | no |
| HMPREF0010_02047 | carbamoyl-phosphate synthase large subunit | no | yes | no | no | no | yes |
| HMPREF0010_02048 | carbamoyl-phosphate synthase small subunit | no | yes | no | no | no | yes |
| HMPREF0010_02972 | argininosuccinate synthase | no | yes | no | no | no | yes |
| HMPREF0010_03445 | 34-dihydroxy-2-butanone 4-phosphate synthase | no | yes | no | no | no | no |
| HMPREF0010_00048 | sugar kinase | no | yes | no | no | no | no |
| HMPREF0010_02330 | glutamine synthetase type I | no | no | yes | no | no | no |
| HMPREF0010_01216 | quinolinate synthetase complex A subunit | no | no | no | yes | no | no |
| HMPREF0010_02175 | thymidylate kinase | no | no | no | yes | no | yes |
| HMPREF0010_03295 | nicotinate-nucleotide diphosphorylase (carboxylating) | no | no | no | yes | no | no |
| HMPREF0010_01705 | ketol-acid reductoisomerase | no | no | no | no | yes | no |
| HMPREF0010_00392 | ornithine-oxo-acid transaminase | no | no | no | no | no | yes |
| HMPREF0010_00419 | N-acetyl-gamma-glutamyl-phosphate reductase | no | no | no | no | no | yes |
| HMPREF0010_00840 | methionine adenosyltransferase | no | no | no | no | no | yes |
| HMPREF0010_01215 | ArgJ protein | no | no | no | no | no | yes |
| HMPREF0010_01382 | acetylglutamate kinase | no | no | no | no | no | yes |
| HMPREF0010_01506 | methionine synthase | no | no | no | no | no | yes |
| HMPREF0010_01669 | 3-methyl-2-oxobutanoate hydroxymethyltransferase | no | no | no | no | no | yes |
| HMPREF0010_01887 | 2-heptaprenyl-14-naphthoquinone methyltransferase | no | no | no | no | no | yes |
| HMPREF0010_01969 | argininosuccinate lyase | no | no | no | no | no | yes |
| HMPREF0010_02002 | riboflavin synthase alpha subunit | no | no | no | no | no | yes |
| HMPREF0010_02344 | adenosylhomocysteinase | no | no | no | no | no | yes |
| HMPREF0010_0275979 | glutamate racemase | no | no | no | no | no | yes |
| HMPREF0010_03444 | 67-dimethyl-8-ribityllumazine synthase | no | no | no | no | no | yes |
Figure 5Venn diagrams proportionally showing EGs predicted only in absence of colistin (pink), EGs predicted only in presence of colistin (green), and EGs predicted by both (blue), at 15 minutes (A) and 60 minutes (B).